These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8434805)

  • 21. Pathogenesis and treatment of Raynaud's phenomenon.
    Coffman JD
    Cardiovasc Drugs Ther; 1990 Jan; 4 Suppl 1():45-51. PubMed ID: 2285650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International study of ketanserin in Raynaud's phenomenon.
    Coffman JD; Clement DL; Creager MA; Dormandy JA; Janssens MM; McKendry RJ; Murray GD; Nielsen SL
    Am J Med; 1989 Sep; 87(3):264-8. PubMed ID: 2672807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of chronic ketanserin treatment on serotonin-induced platelet aggregation in patients with Raynaud's phenomenon.
    Marasini B; Biondi ML; Mollica R
    Eur J Clin Pharmacol; 1990; 39(3):289-90. PubMed ID: 2257869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.
    Roald OK; Seem E
    Br Med J (Clin Res Ed); 1984 Sep; 289(6445):577-9. PubMed ID: 6432198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon.
    Brouwer RM; Wenting GJ; Man in't Veld AJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S26-31. PubMed ID: 2446064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy.
    Kunnen JJ; Dahler HP; Doorenspleet JG; van Oene JC
    Eur J Clin Pharmacol; 1988; 34(3):267-71. PubMed ID: 2840293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.
    Marasini B; Biondi ML; Bianchi E; Dell'Orto P; Agostoni A
    Eur J Clin Pharmacol; 1988; 35(4):419-21. PubMed ID: 3197751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Raynaud's phenomenon. An update.
    Coffman JD
    Hypertension; 1991 May; 17(5):593-602. PubMed ID: 2022404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of Raynaud's phenomenon].
    Lazareth I
    Ann Dermatol Venereol; 1987; 114(8):1035-8. PubMed ID: 2892456
    [No Abstract]   [Full Text] [Related]  

  • 30. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis.
    Lau CS; Belch JJ; Madhok R; Cappell H; Herrick A; Jayson M; Thompson JM
    Clin Exp Rheumatol; 1993; 11(1):35-40. PubMed ID: 8453795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The effect of beraprost sodium on the Raynaud's phenomenon].
    Hiida M; Ushiyama O; Suzuki N; Ohta A; Nagasawa K; Yamaguchi M
    Nihon Rinsho Meneki Gakkai Kaishi; 1996 Jun; 19(3):193-200. PubMed ID: 8810544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Microcirc Endothelium Lymphatics; 1985; 2(6):657-85. PubMed ID: 2942753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged remission in Raynaud's phenomenon after prostacyclin infusion.
    Bellucci S; Kedra AW; Courmelle JM; Maclouf J; Boizard B; Dosquet-Bernard C; Tobelem G; Caen JP
    Scand J Rheumatol; 1986; 15(4):392-8. PubMed ID: 3547631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypertensive patients with Raynaud's phenomenon or intermittent claudication and their treatment with ketanserin.
    van Oene JC
    Drugs; 1988; 36 Suppl 1():148-51. PubMed ID: 3240729
    [No Abstract]   [Full Text] [Related]  

  • 35. Digital blood flow and 5-hydroxytryptamine receptor blockade after ketanserin in patients with Raynaud's phenomenon.
    Marasini B; Bassani C
    Br J Clin Pharmacol; 1990 Dec; 30(6):847-51. PubMed ID: 2288831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of Raynaud's syndrome with ketanserin. Clinical, biological and hemodynamic aspects].
    Bellucci S; Kedra AW; Naccache-Herman V; Cambau E; Tobelem G; Caen JP
    Presse Med; 1987 Jul 11-18; 16(27):1335. PubMed ID: 2956601
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of ketanserin in the therapy of Raynaud's phenomenon: thermometric data.
    Arosio E; Montesi G; Zannoni M; Perbellini L; Paluani F; Lechi A
    Angiology; 1991 May; 42(5):408-13. PubMed ID: 2035893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cold-induced Raynaud's phenomenon ameliorated by intravenous administration of ketanserin: a double-blind cross-over study.
    Baart de la Faille H; van Weelden H; Banga JD; van Kesteren RG
    Arch Dermatol Res; 1986; 279(1):3-7. PubMed ID: 3545103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Raynaud's disease and prostacyclin.
    Kennerly D
    Ann Intern Med; 1983 Feb; 98(2):258. PubMed ID: 6337542
    [No Abstract]   [Full Text] [Related]  

  • 40. Raynaud's phenomenon.
    Belch JJ
    Curr Opin Rheumatol; 1989 Dec; 1(4):490-8. PubMed ID: 2702051
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.